Fire safety standards, including the application of flame-retardant chemicals, have been established in modern societies to reduce deaths and injuries as well as economic impact of fires. Bromine, like other halogens, quenches free radicals generated in a fire with high efficiency, thereby preventing the propagation of a flame. In Europe and North America, brominated flame retardants (BFRs) are therefore commonly used in household applications. BFRs were established as the major chemical flame retardant in the 1970s after the discovery of the adverse effects of polychlorinated biphenyls (PCBs) on human and environmental health and in experimental studies (for reviews, see [@r37]; [@r100]). BFRs are a structurally diverse group of chemicals, with polybrominated diphenyl ethers (PBDEs) ([Table 1](#t1){ref-type="table"}) being among the formerly most highly produced BFRs ([@r12]).

###### 

Individual PBDEs discussed in this review.

  ----------------------------------------------------- -- --------------------------------------------------------
  Table 1. Individual PBDEs discussed in this review.      
  Abbreviation                                             Name
  BDE-47                                                   2,2´,4,4´-Tetrabrominated diphenyl ether
  BDE-49                                                   2,2´,4,5´-Tetrabrominated diphenyl ether
  BDE-99                                                   2,2´,4,4´,5-Pentabrominated diphenyl ether
  BDE-100                                                  2,2´,4,4´,6-Pentabrominated diphenyl ether
  BDE-153                                                  2,2´,4,4´,5,5´-Hexabrominated diphenyl ether
  BDE-183                                                  2,2´,3,4,4´,5´,6-Heptabrominated diphenyl ether
  BDE-203                                                  2,2´,3,4,4´,5,5´,6-Octabrominated diphenyl ether
  BDE-206                                                  2,2´,3,3´,4,4´,5,5´,6-Nonabrominated diphenyl ether
  BDE-209                                                  2,2´,3,3´,4,4´,5,5´,6,6´-Decabrominated diphenyl ether
  DE-71                                                    Commercial pentaBDE product
  6-MeO-BDE-47                                             6-Methoxy-2,2´,4,4´-tetrabrominated diphenyl ether
  6-OH-BDE-47                                              6-Hydroxy-2,2´,4,4´-tetrabrominated diphenyl ether
  ----------------------------------------------------- -- --------------------------------------------------------

Although PBDEs are globally dispersed throughout the environment (reviewed by [@r65]), human and environmental levels of PBDEs are approximately one order of magnitude higher in North America than in Europe and Asia (reviewed by [@r38]). Humans are exposed to PBDEs in particular via air and ingestion of house dust, but also through intake of vegetable and animal products (reviewed by [@r38]). Because of their relatively high food intake, child-specific hand-to-mouth behavior, and frequent ground contact (resulting in the ingestion of house dust), children are exposed to larger amounts of PBDEs than are adults ([@r36]; [@r111]). An additional source of exposure for young children is breast milk, in which especially lower brominated PBDEs have been detected (reviewed by [@r38]). Prenatal exposure to PBDEs occurs through placental transfer \[[@r44]; [@r75]; see Supplemental Material, [Table 1](#t1){ref-type="table"} (doi:10.1289/ehp.1003035)\].

Toxicokinetics studies have revealed the formation of methoxylated (MeO-) and hydroxylated (OH-)PBDEs *in vivo* ([@r71]; [@r107]; [@r128]; see also Supplemental Material (doi:10.1289/ehp.1003035)\] and *in vitro* ([@r47]; [@r105]; [@r128]). Interestingly, OH-PBDEs and MeO-PBDEs have also been detected as natural products in marine algae, cyanobacteria, and sponges (e.g., [@r72]; [@r110]). Human exposure studies have revealed that various OH-PBDEs are present in serum at concentrations similar to or sometimes higher than those of parent PBDEs ([@r6]; [@r87]; see Supplemental Material, [Table 1](#t1){ref-type="table"}).

Since the start of this century, exposure to BFRs has been associated with (developmental) neurotoxicity ([@r32]). Recently, adverse effects on cognitive and neurodevelopmental parameters in humans were correlated to exposure to PBDEs. Motor, cognitive, and behavioral performance in 6-year-old Dutch children was correlated with maternal serum levels of PBDEs measured in the 35th week of pregnancy ([@r94]). In another study, the scores of U.S. children 0--6 years of age on yearly tests of mental and physical development were lower among those prenatally exposed to higher concentrations of PBDEs ([@r52]).

In this review we extend knowledge from previous reviews of underlying mechanisms of adverse effects on the nervous system by exposure to PBDEs ([@r21]; [@r37]) and also focus on the contribution of OH-PBDEs to PBDE-induced neurotoxicity.

Toxicity of PBDEs: Target Organs
================================

Early acute *in vivo* toxicity studies have revealed only moderate effects of PBDEs at high exposure concentrations, mainly in the liver and thyroid gland ([@r48]). The first studies on the toxic mechanisms of PBDEs investigated the possible effects of PBDEs on aryl hydrocarbon receptor (AhR)-mediated processes because of their structural resemblance to AhR-activating compounds (e.g., some PCBs). Although effects of PBDEs were detected on gene induction and activity of hepatic enzymes *in vivo* and *in vitro* ([@r116]), the observed AhR-mediated effects of commercial PBDE mixtures are now generally considered to be caused by trace amounts of brominated dioxins and furans, which are potent inducers of cytochrome P450 (CYP) 1A and 1B enzymes ([@r95]; [@r116]; [@r126]). A lack of activation of the AhR by PBDEs, probably because of their lack of a planar-like structure, was recently confirmed in primary hepatocytes and hepatic cell lines ([@r125]).

Endocrine and reproductive effects of PBDEs have been detected, in particular in wild birds and experimental studies with rodents ([@r22]; [@r35]; [@r64]). In epidemiological studies, exposure to PBDEs has been associated more recently with congenital cryptorchidism in Danish children ([@r69]) and decreased fecundability ([@r49]).

*In vitro* studies have demonstrated that PBDEs and OH-PBDEs bind to estrogen, progesterone, androgen, and glucocorticoid receptors and inhibit CYP enzymes involved in steroidogenesis ([Table 2](#t2){ref-type="table"}) ([@r63]; [@r77]). Several studies have revealed that the potency of OH-PBDEs for these end points is higher than for their parent compounds, whereas MeO-PBDEs showed no or smaller effects ([Table 2](#t2){ref-type="table"}) ([@r13], [@r14]; [@r46]; [@r79]).

###### 

Effects and effect concentrations of BDE-47, 6-OH-BDE-47, and 6-MeO-BDE-47.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -- ------------------------------------------- -- ------------------------------ -- --------------------------- -- ------------- -- --------------
  Table 2. Effects and effect concentrations of BDE-47, 6-OH-BDE-47, and 6-MeO-BDE-47.                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                             Effect concentration (μM)                       
  Test system (study)                                                                                                                                                                                                                                                                                                                       Effect                                         Exposure duration                 BDE-47                         6-OH-BDE-47      6-MeO-BDE-47
  Human hepatoma (HepG2) cells (An et al. 2010)                                                                                                                                                                                                                                                                                             Reduced cell viability                         LOEC (72 hr)                      ---                            0.5              5
                                                                                                                                                                                                                                                                                                                                            Cell cycle block                               LOEC (48 hr)                      ---                            0.5              NE (≤ 5)
                                                                                                                                                                                                                                                                                                                                            ROS generation                                 LOEC (24 hr)                      ---                            0.1              2
  Human adrenocortical carcinoma (H296R) cells (Cantón et al. 2005, 2006)                                                                                                                                                                                                                                                                   Reduced cell viability                         LOEC (24 hr)                      NE (≤ 7.5)                     2.5              NE (≤ 7.5)
  Aromatase activity inhibition                                                                                                                                                                                                                                                                                                             LOEC (24 hr)                                   NE (≤ 7.5)                        2.5                            5                
  CYP17 activity inhibition                                                                                                                                                                                                                                                                                                                 LOEC (24 hr)                                   NE (≤ 10)                         1                              10               
  Human adrenocortical carcinoma (H296R) cells (Song et al. 2008)                                                                                                                                                                                                                                                                           Reduced cell viability                         LOEC (48 hr)                      NE (≤ 0.5)                     NE (≤ 0.5)       NE (≤ 0.5)
  Aromatase activity inhibition                                                                                                                                                                                                                                                                                                             LOEC (48 hr)                                   NE (≤ 0.5)                        NE (≤ 0.5)                     NE (≤ 0.5)       
  Human placental microsomes (Cantón et al. 2008)                                                                                                                                                                                                                                                                                           Aromatase activity inhibition                  IC~50~ (40 min)                   ---                            7.44             NE (≤ 40)
  Nuclear hormone receptors transfected in CALUX cell lines (Hamers et al. 2006)                                                                                                                                                                                                                                                            AhR                                            EC~50~ (24 hr)                    NE (≤ 10)                      1.3 ± 0.4        ---
  AhR                                                                                                                                                                                                                                                                                                                                       IC~50~ (24 hr)                                 2.7 ± 0.7                         NE (≤ 10)                      ---              
  Androgen receptor                                                                                                                                                                                                                                                                                                                         IC~50~ (24 hr)                                 1.0 ± 0.2                         2.8 ± 0.4                      ---              
  Progesterone receptor                                                                                                                                                                                                                                                                                                                     IC~50~ (24 hr)                                 \> 15                             5.0 ± 0.9                      ---              
  Estrogen receptor                                                                                                                                                                                                                                                                                                                         EC~50~ (24 hr)                                 12 ± 4                            NE (≤ 12.5)                    ---              
  Estrogen receptor                                                                                                                                                                                                                                                                                                                         IC~50~ (24 hr)                                 NE (≤ 12.5)                       0.45 ± 0.03                    ---              
  Human TTR (Hamers et al. 2006)                                                                                                                                                                                                                                                                                                            TTR binding (T~4~ competition)                 IC~50~ (binding equilibrium)      \> 25                          0.18             ---
  Human TTR (Marchesini et al. 2008)                                                                                                                                                                                                                                                                                                        TTR binding (T~4~ competition; biosensor)      IC~50~ (binding equilibrium)      NR (≤ 1)                       0.087            NR (1.8)
  Human TBG (Marchesini et al. 2008)                                                                                                                                                                                                                                                                                                        TBG binding (T~4~ competition; biosensor)      IC~50~ (binding equilibrium)      NR (≤ 10)                      0.11             NR (10)
  Zebrafish (van Boxtel et al. 2008)                                                                                                                                                                                                                                                                                                        Abnormal development                           EC~50~ (72 hr)                    NE (≤ 10)                      0.025            NE (≤ 10)
                                                                                                                                                                                                                                                                                                                                            Mortality (adult)                              EC~50~ (96 hr)                    NE (≤ 0.5)                     0.3              ---
  Neurotransmitter receptors expressed in *Xenopus* oocytes (Hendriks et al 2010)                                                                                                                                                                                                                                                           GABA~A~-receptor full agonism                  LOEC (20 sec)                     NE (≤ 10)                      10               ---
  GABA~A~-receptor partial agonism                                                                                                                                                                                                                                                                                                          LOEC (10 sec)                                  NE (≤ 10)                         10                             ---              
  nACh-receptor antagonism                                                                                                                                                                                                                                                                                                                  LOEC (5 sec)                                   NE (≤ 10)                         10                             ---              
  Rat PC12 cells (Dingemans et al. 2010a)                                                                                                                                                                                                                                                                                                   Induction of \[Ca^2+^\]*i* oscillations        LOEC (20 min)                     2                              0.2              NE (≤ 20)
                                                                                                                                                                                                                                                                                                                                            Ca^2+^ release from intracellular stores       LOEC (20 min)                     NE (≤ 20)                      1                NE (≤ 20)
  Abbreviations: ---, not investigated; EC~50~, half-maximal effect concentration; GABA~A~, γ‑aminobutyric acid‑A; IC~50~, half-maximal inhibitory concentration; LOEC, lowest observed effect concentration; nACh, nicotinic acetylcholine; NE, no effect; NR, not reached; ROS, reactive oxygen species; TBG, T~4~-binding globulin.                                                                                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -- ------------------------------------------- -- ------------------------------ -- --------------------------- -- ------------- -- --------------

Epidemiological studies also showed correlations between human PBDE exposure and thyroid hormone levels ([@r19]; [@r113]; [@r132]). PBDEs and particularly OH-PBDEs structurally resemble the thyroid hormone thyroxin (T~4~) and have been found to bind to transthyretin (TTR), a thyroid hormone transport protein, and thyroid receptors α and β ([Table 2](#t2){ref-type="table"}) ([@r78]). Effects of PBDEs and PBDE mixtures on the thyroid hormone system, mainly a decrease in T~4~ (hypothyroidism), were confirmed *in vivo* in rodents exposed prenatally and/or neonatally ([@r30]; [@r66]; [@r90]; [@r112]; [@r135]) or in adulthood ([@r23]; [@r92]). Developmental exposure to low doses of BDE-47 (2,2´,4,4´-tetrabrominated diphenyl ether) resulted in changes in thyroid gland histology and morphology in rats ([@r108]). In addition, a few studies found a reduction in the biologically active thyroid hormone triiodothyronine (T~3~) in serum of rats exposed to PBDEs ([@r66]; [@r112]).

Neurotoxicity of PBDEs: Behavioral Effects
==========================================

[@r32] exposed mice to a single oral dose of BDE-47 and BDE-99 (2,2´,4,4´,5-pentabrominated diphenyl ether) on postnatal day (PND) 10 and observed dose-dependent effects on spontaneous behavior (locomotion, rearing, and total activity) and Morris water maze relearning abilities of 2- and 4-month-old mice. Habituation capability also decreased with age in mice exposed to BDE-47 and BDE-99 compared with controls. This exposure regimen has been used to investigate effects of different PBDE congeners on spontaneous behavior. Similar long-lasting neurobehavioral changes have now been detected after a single oral dose of BDE-153 (2,2´,4,4´,5,5´-hexabrominated diphenyl ether), BDE-183 (2,2´,3,4,4´,5´,6-heptabrominated diphenyl ether), BDE-203 (2,2´,3,4,4´,5,5´,6-octabrominated diphenyl ether), BDE-206 (2,2´,3,3´,4,4´,5,5´,6-nonabrominated diphenyl ether), or BDE-209 (2,2´,3,3´,4,4´,5,5´,6,6´-decabrominated diphenyl ether) administered to neonatal mice ([@r58]; [@r120], [@r123]). Further research has demonstrated effects of PBDEs on behavioral end points and performance in learning tasks in rodents after neonatal administration of a single oral dose, developmental exposure, or repeated neonatal dosing ([@r11]; [@r31]; [@r64]). In a recent study, [@r17] reported impaired reflexes and Morris water maze relearning abilities in rats exposed to BDE-99 from gestation through lactation. Several developmental end points of motor activity and coordination were affected in mice exposed to a single oral dose of BDE-47 on PND10 ([@r42]). By operant conditioning (reward-reinforced learning) of mice, increased impulsivity was observed in aging mice after neonatal exposure to BDE-209, whereas no effects were observed in littermates tested during young adulthood ([@r91]). In another study, rats were chronically exposed to the commercial pentaBDE mixture DE-71 during lactation and through feed, which was continued through testing, to mimic low-level chronic human exposure ([@r30]); no effects were observed on operant conditioning in adult rats, although their attention spans were impaired. This impaired attention is consistent with previously reported hyperactivity (i.e., increased locomotor activity) in animals postnatally exposed to various PBDEs (e.g., [@r32]), although it may also be related to the presence of brominated dioxins and furans in this commercial PBDE mixture.

The aforementioned studies strongly suggest that exposure to PBDEs causes adverse neurobehavioral effects, in particular during early neurodevelopment. With respect to neonatal exposure, a study in which BDE-99 was administered on PND3, PND10, or PND19 ([@r33]) revealed that brain development in mice is most sensitive to exposure to PBDEs in the first 2 weeks after birth. In rats and mice, rapid growth of the brain, as well as synaptogenesis and myelination, occurs within these 2 weeks, whereas in humans these processes start in the last trimester of pregnancy and extend into early childhood (for reviews, see [@r28]; [@r89]; [@r109]).

Neurotoxicity of PBDEs: Effects on Brain Function and Structure
===============================================================

Using the same exposure regimen previously shown to affect neurobehavior ([@r32]), [@r26] found that neonatal exposure to BDE-47 impaired long-term potentiation (LTP), a form of synaptic plasticity associated with learning and memory, measured *ex vivo* in hippocampal slices. Recently, [@r129] reported that developmental exposure to the fully brominated BDE-209 also reduced LTP, as measured *in vivo* in the dentate gyrus of the hippocampus in rats. Rat offspring were exposed orally or via the mother to BDE-209 during different developmental periods (pregnancy, lactation, and after weaning). Decreases in synaptic plasticity were related to hippocampal BDE-209 concentrations, which were highest after intragastric exposure during the lactational period compared with after exposure via the mother (gestational or via lactation) or directly to the pups after weaning ([@r129]).

Developmental exposure \[gestational days (GDs) 2--9\] to BDE-99 resulted in increased activity of the glutamate--nitric oxide--cyclic guanosine monophosphate pathway in rat cerebellum ([@r67]). This pathway is involved in the modulation of cerebral processes, including the release of neurotransmitters and synaptic plasticity ([@r10]). Surprisingly, this increased activity coincided with a slightly enhanced performance in a learning task ([@r67]).

Several studies have revealed effects of PBDEs on neurotransmitter receptor function and brain protein levels ([Table 3](#t3){ref-type="table"}). Effects of PBDEs on the cholinergic neurotransmitter system in rodents were revealed primarily by hypoactive responses to neurotransmitter receptor agonists ([@r58]; [@r119]). Particularly in hippocampus, but also in cortex and striatum, alterations in levels of key proteins involved in synaptic plasticity and brain development were detected after exposure to PBDEs ([@r2]; [@r26]; [@r124]). Effects were observed after exposure to either tetra- and pentaBDEs or octa- through decaBDEs.  Potency differences between different PBDE congeners or degrees of bromination were not apparent.

###### 

Effects of PBDE exposure on brain structure in rodents after oral administration during PNDs 1--14.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -- --------- -- -------------------------------------------- -- -----------------------
  Table 3. Effects of PBDE exposure on brain structure in rodents after oral administration during PNDs 1--14.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Species                                                                                                                                                                                                                                                                                                                                                                        Effect                                                                                                                                                                                                          PBDE         Effect concentration (μmol/kg body weight)      Reference
  C57Bl/6 mouse                                                                                                                                                                                                                                                                                                                                                                  Decreased GluR subunit NR2B, GluR subunit GluR1, and p286-αCaMKII in hippocampal PSD (Western blot)                                                                                                             BDE-47       14                                              Dingemans et al. 2007
  NMRI mouse                                                                                                                                                                                                                                                                                                                                                                     Decreased nAChR (decreased ^3^H-α-bungarotoxin binding)*a*                                                                                                                                                      BDE-99       21                                              Viberg et al. 2004
  NMRI mouse                                                                                                                                                                                                                                                                                                                                                                     Decreased nAChR (decreased ^3^H-α-bungarotoxin binding)*a*                                                                                                                                                      BDE-99       14                                              Viberg et al. 2002
  NMRI mouse                                                                                                                                                                                                                                                                                                                                                                     Alteration in hippocampal proteins (mainly proteins involved in metabolism and energy production, and in striatal proteins (mainly proteins involved in neurodegeneration and neuroplasticity; proteomics)      BDE-99       21                                              Alm et al. 2006
  NMRI mouse                                                                                                                                                                                                                                                                                                                                                                     Alteration in cortical proteins (mainly cytoskeletal related; proteomics)                                                                                                                                       BDE-99       21                                              Alm et al. 2008
  NMRI mouse                                                                                                                                                                                                                                                                                                                                                                     Decreased nAChR (decreased ^3^H-α-bungarotoxin binding)*a*                                                                                                                                                      BDE-153      14                                              Viberg et al. 2003
  NMRI mouse                                                                                                                                                                                                                                                                                                                                                                     Increased CaMKII and synaptophysin in hippocampus                                                                                                                                                               BDE-203      21                                              Viberg 2009a
  NMRI mouse                                                                                                                                                                                                                                                                                                                                                                     Increased CaMKII and synaptophysin in hippocampus                                                                                                                                                               BDE-206      21                                              Viberg 2009a
  Sprague-Dawley rat                                                                                                                                                                                                                                                                                                                                                             Decreased nAChR (hypoactive *in vivo* nicotine response)*a*                                                                                                                                                     BDE-209      21                                              Viberg et al. 2007
  NMRI mouse                                                                                                                                                                                                                                                                                                                                                                     Decreased nAChR (hypoactive *in vivo* nicotine response)*a*                                                                                                                                                     BDE-209      14                                              Johansson et al. 2008
  NMRI mouse                                                                                                                                                                                                                                                                                                                                                                     Decreased BDNF and increased CaMKII and GAP-43 in hippocampus, decreased GAP-43 in cortex                                                                                                                       BDE-209      21                                              Viberg et al. 2008
  NMRI mouse                                                                                                                                                                                                                                                                                                                                                                     Increased synaptophysin in hippocampus                                                                                                                                                                          BDE-209      21                                              Viberg 2009b
  Abbreviations: BDNF, brain-derived neurotrophic factor; CaMKII, Ca^2+^/calmodulin-dependent protein kinase II; GAP-43, growth-associated protein-43; GluR, glutamate receptor; nAChR, nACh receptor; p286-αCaMKII, autophosphorylated-active Ca^2+^/calmodulin-dependent protein kinase II; PSD, postsynaptic density. **a**Effects were detected on a whole-brain level.                                                                                                                                                                                                                                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -- --------- -- -------------------------------------------- -- -----------------------

[@r8] detected markers for oxidative stress in the cerebellum and, to a lesser extent, in cortex and hippocampus of adult rats exposed to BDE-99 at 0.6 mg/kg body weight. In another study, [@r17] observed increased oxidative stress in the hippocampus (not in cerebellum and cerebral cortex) of rats exposed from GD6 to PND21 to BDE-99 at 2 mg/kg body weight via their mother (transplacental and lactational exposure). Only in this study ([@r17]) were behavioral effects detected as well--- perhaps related to the higher dose, but more likely related to the timing of the exposure (i.e., during neurodevelopment).

Neurotoxicity of PBDEs: Cellular and Molecular Mechanisms
=========================================================

*Cell viability.* In several *in vitro* studies, tetra- and pentaBDEs were found to induce apoptotic cell death in primary neurons or neuronal cell lines, which appeared to be a consequence of oxidative stress ([@r43]; [@r50]; [@r68]; [@r88]; [@r131]). Recently, the fully brominated BDE-209 was also shown to increase apoptotic cell death and oxidative stress in rat primary hippocampal neurons ([@r16]). This effect may not be specifically neurotoxic, but neuronal cells are particularly vulnerable to oxidative stress because relatively high levels of reactive oxygen species (ROS) are generated during normal metabolism and neuronal activity. It appears that the antioxidant capacity of enzymes that are able to react with and inactivate ROS is exceeded after exposure to PBDEs, resulting in oxidative stress and subsequent damage of DNA, proteins, and membrane lipids.

*Cell differentiation and migration.* Differentiation and migration are critical processes in neurodevelopment. During *in vitro* exposure to BDE-209, neurite outgrowth and the differentiation of neural stem cells into neurons were dose-dependently inhibited \[lowest observed effect concentration (LOEC), 10 μM\]. Instead, a larger proportion of the neural stem cells differentiated into glial cells ([@r133]). In another study, [@r98] observed a decrease in the number of cells differentiating to neuron-like or oligodendrocyte-like cell types when human neural progenitor cells were exposed to 1 μM BDE-47 or BDE-99. Moreover, these *in vitro* experiments demonstrated decreased migration of human neural progenitor cells exposed to BDE-47 or BDE-99 ([@r98]), confirming previously suggested functional effects on cell migration, based on proteomics studies ([@r1]). In cultured fetal rat cortical cells, BDE-99--induced changes were also detected in levels of proteins involved in formation of the cytoskeleton that is involved in cellular migration ([@r3]).

*Neuronal signaling.* PBDEs (mainly tetra- and pentaBDEs) have been shown to affect several aspects of inter- and intraneuronal signaling, including inhibition of neurotransmitter uptake in synaptosomes and neurotransmitter vesicles and alterations in calcium (Ca^2+^) homeostasis ([@r62]; [@r74]). DE-71 has recently been shown to reduce synaptosomal dopamine levels and increase medium dopamine concentrations in a system with isolated rat striatal synaptosomes, probably by inhibition of the membrane dopamine transporter ([@r29]). In addition to effects on neurotransmitter uptake, BDE-47 (20 μM) induced vesicular neurotransmitter release by exocytosis in PC12 pheochromocytoma cells ([@r26]). Importantly, the BDE-47 metabolite 6-OH-BDE-47 (5 μM) induced a more pronounced increase in exocytosis in PC12 cells within several minutes after the start of exposure ([@r24]). The observed increases in exocytosis were paralleled by increases in intracellular calcium concentration (\[Ca^2+^\]*~i~*). At 2 μM, BDE-47 induced only subtle changes in Ca^2+^ homeostasis that manifested as increased frequency and duration of fluctuations in \[Ca^2+^\]*~i~*, whereas no effects were observed on \[Ca^2+^\]*~i~* when PC12 cells were exposed to BDE-49 (2,2´,4,5´-tetrabrominated diphenyl ether), BDE-99, BDE-100 (2,2´,4,4´,6-pentabrominated diphenyl ether), or BDE-153 ([@r25]). On the other hand, 6-OH-BDE-47 (6-hydroxy-2,2´,4,4´-tetrabrominated diphenyl ether; ≥ 1 μM) caused a rapid, robust increase in \[Ca^2+^\]*~i~* by release from endoplasmic reticulum followed by release from mitochondria. Similar effects were detected for other OH-PBDEs \[6-MeO-BDE-47 (6-methoxy-2,2´,4,4´-tetrabrominated diphenyl ether) showed no effect\]; although the potency to disturb calcium homeostasis depended on the presence of large atomic groups (bromine atom or aromatic ring) adjacent to the OH, the hydroxylation position was of lesser importance ([@r25]). Although release of calcium from intracellular stores was not detected during exposure to parent PBDEs, DE-71, BDE-47, and BDE-99 have been shown to inhibit uptake of Ca^2+^ in microsomes and mitochondria isolated from rat cortex, cerebellum, and hippocampus ([@r20]). BDE-47 and OH-PBDEs that increased basal \[Ca^2+^\]*~i~* subsequently inhibited the depolarization-evoked increase in \[Ca^2+^\]*~i~* in PC12 cells at similar LOECs ([@r27]). Although this appeared to be a direct inhibitory effect on calcium entry, it was strongly potentiated by preceding increases in basal \[Ca^2+^\]*~i~* before depolarization, suggesting additional Ca^2+^-dependent regulatory mechanisms ([@r27]).

PBDEs have also been shown to affect several aspects of intracellular signaling pathways that are involved in Ca^2+^ homeostasis and Ca^2+^ signaling ([@r39]) by inducing protein kinase C translocation and arachidonic acid release via phospholipase A activation ([@r61]; [@r62]; [@r68]). In cerebellar granule neurons, PBDE congeners and commercial mixtures (low micromolar range) also activated the mitogen-activated protein kinase pathway ([@r34]), which is involved in the modulation of various cellular functions and in turn is modulated by both protein kinase C and Ca^2+^ ([@r85]; [@r97]).

BDE-209 dose-dependently decreased voltage-gated sodium channel currents in primary rat hippocampal neurons ([@r130]). Recently, full and partial agonistic effects on the γ-aminobutyric acid-A (GABA~A~) receptor and antagonistic effects on the α~4~β~2~ nicotinic acetylcholine (nACh) receptor (expressed in *Xenopus* oocytes) were demonstrated for 6-OH-BDE-47, whereas these effects were not observed for BDE-47 ([@r51]). Because interactions of GABAergic, cholinergic, and glutaminergic neurotransmitters are critical for the development of neuronal networks during brain development ([@r9]), these opposite effects on excitatory (nACh) and inhibitory (GABA) neurotransmitter receptor effects suggest an important role of the OH-PBDEs in the observed *in vivo* neurotoxicity of PBDEs.

Together, these *in vitro* studies indicate that lower brominated PBDEs (tetra- and pentaBDEs) affect all levels of neurotransmission, from presynaptic neurotransmitter homeostasis, intracellular signaling, and neurotransmitter release to postsynaptic neurotransmitter receptors. For some neurotoxic end points, it is evident that OH-PBDEs have a higher potency than their parent congeners ([Table 2](#t2){ref-type="table"}), whereas this is unclear for other end points. Because intracellular signaling pathways, calcium homeostasis, and oxidative stress are interrelated, the main molecular target of (OH-)PBDEs remains unclear. However, the combination of results from several studies showing oxidative stress or mitochondrial Ca^2+^ release (or inhibition of Ca^2+^ uptake) suggests that mitochondria are a primary target for PBDE toxicity. This is supported by the observation of accumulation of PBDEs in mitochondria in mouse primary neurons ([@r56]). A combination of the observed cellular and molecular mechanisms could be involved in the observed neurobehavioral impairments. In particular, OH-PBDEs have been shown to alter neurotransmitter release patterns and underlying (Ca^2+^) signaling pathways. Influence of transient alterations in \[Ca^2+^\]*~i~* on brain development is not unlikely, because Ca^2+^ signals are essential in (early) brain development (for reviews, see [@r81]; [@r104]) and the induction of synaptic plasticity (for reviews, see [@r70]; [@r102]). Small changes in catecholaminergic modulation can have effects on behavior ([@r5]). Temporary alterations of neuronal activity during critical periods in brain development could therefore underlie the observed effects on behavior and hippocampal synaptic plasticity. The concentrations at which effects of parent PBDEs are observed *in vitro* are very different from human exposure levels. However, few *in vitro* studies take into account the low solubility of PBDEs or the binding of PBDEs to serum proteins and cell culture materials, resulting in overestimation of cellular exposure concentrations. In contrast, accumulation into cells has also been demonstrated to occur, resulting in the possible underestimation of intracellular PBDE concentrations after (sub)chronic exposure ([@r56]; [@r83]).

Conclusion and Discussion
=========================

Behavioral studies clearly indicate the neurotoxic potential of PBDEs. Importantly, several mechanistic studies indicate that this neurotoxic potential is higher for the OH-PBDEs. At least two effects of PBDEs or their metabolites are expected to be involved in developmental neurotoxicity, resulting in structural and functional alterations in the brain and, ultimately, behavioral effects ([Figure 1](#f1){ref-type="fig"}). On the one hand, direct toxic effects on the (developing) nervous system are likely involved in PBDE-induced developmental neurotoxicity. On the other hand, PBDEs have been shown to affect the thyroid hormone system. Because thyroid hormones are critically involved in (early) brain development (for reviews, see [@r54]; [@r55]), this mechanism is likely involved in the PBDE-induced neurotoxicity.

![Direct and indirect PBDE-induced developmental neurotoxicity. Observed end points for which larger effects have been detected for OH-PBDEs are shown in blue.](ehp.1003035.g001){#f1}

In humans, thyroid hormone production starts at approximately 10 weeks of gestation and increases with the development of the fetal hypothalamic--pituitary--thyroid axis (reviewed by [@r55]). However, transplacental transfer of maternal thyroid hormones to the fetus is critical for neurodevelopment. Impaired psychomotor development and visuospatial processing have been revealed in children born to mothers with (subclinical) hypothyroidism ([@r45]; [@r86]). Prenatal and postnatal hypothyroidism are associated with behavioral deficits in humans as well as animal models (reviewed by [@r137]).

On a cellular level, effects of thyroid hormones have been shown to be involved in neuronal proliferation, migration, synaptogenesis, synaptic plasticity, and myelation processes (for reviews, see [@r54]; [@r55]). Interestingly, several of these processes (described above) have been shown to be directly affected by PBDEs or their metabolites, and adverse effects comparable to those observed after developmental exposure to BFRs are also observed in animal models of moderate or transient insufficiency in thyroid hormone levels, commonly induced by exposure to propylthiouracil (reviewed by [@r136]).

*In vitro* studies with 6-OH-BDE-47 show that effect concentrations for displacement of T~4~ from the hormone transport protein TTR and induction of \[Ca^2+^\]*~i~* oscillations are within the same order of magnitude (\~ 0.2 μM; [Table 2](#t2){ref-type="table"}). Several animal studies have simultaneously investigated both PBDE-induced neurotoxicity and effects on thyroid hormone levels. In rodents in which neonatal exposure to DE-71 and BDE-209 caused effects on neurobehavior, hypothyroidism was also observed ([@r30]; [@r90]). Experimentally induced hypothyroidism has been shown to result in a decrease in cholinergic nerve endings ([@r96]). Therefore, the disruption of normal brain development by (OH-)PBDE-induced hypothyroidism may be an underlying mechanism for the observed PBDE-induced alterations in the cholinergic neurotransmitter system in rodents. However, other mechanisms are likely involved, because thyroid hormone levels were not affected in mice exposed at PND10 to a single oral dose of BDE-47, which is known to result in behavioral effects ([@r41]). On the other hand, for rat dams and offspring with very low levels of T~4~ after developmental exposure to DE-71, an effect was detected in only one of several behavioral tests ([@r60]). This indicates that other mechanisms are also involved in PBDE-induced behavioral neurotoxicity, and that these may differ for various (behavioral) neurotoxic end points and timing of exposure. Further investigation is required to determine the relative contributions or possible effect additivity of the direct and indirect (via thyroid disruption) neurotoxic effects of (OH-)PBDEs in humans. Future studies on thyroid disruption also have to take into account that thyroid hormone levels within brain tissue are more informative of possible thyroid-related effects, because cellular actions of thyroid hormones are initiated at nuclear receptors (reviewed by [@r18]).

The binding of PBDEs and especially OH-PBDEs to receptors and transport proteins involved in thyroid homeostasis and function is the expected mode of action of PBDE-induced hypothyroidism ([@r73]; [@r78]; [@r99]; [@r114]). However, other interactions with the thyroid system, for example, inhibition of iodine uptake such as observed for perchlorate (reviewed by [@r59]), are also possible and require further study. It has been revealed only recently that BDE-209 inhibits thyroid-hormone--induced dendrite arborization of rat Purkinje cells, probably via partial dissociation of thyroid receptors from the binding domain on the thyroid-receptor--responsive element ([@r57]). It is commonly assumed that up-regulation of thyroid- stimulating hormone and deiodinase activity in the brain compensates for reductions in brain T~4~ levels. However, it has recently been revealed that compensatory mechanisms do not prevent effects on thyroid hormone targets in the brain resulting from small reductions in serum T~4~ ([@r101]).

Various environmental pollutants can disrupt thyroid homeostasis (reviewed by [@r59]). Especially if effects on thyroid homeostasis coincide with direct neurotoxicity, as observed for PBDEs, developmental neurotoxicity has to be anticipated. Iodine deficiency, a common condition worldwide (reviewed by [@r127]), is an additional risk factor to increase the sensitivity to adverse effects from thyroid-disrupting chemicals.

Because of the strict temporal regulation of brain development processes, certain time windows are particularly sensitive to neurotoxic insults. Although brain development in humans extends into early childhood, the perinatal period of brain development ("brain growth spurt"; last trimester to 1--2 years of age) has especially been proven to be very sensitive to neurotoxic effects (reviewed by [@r89]). It is currently difficult to estimate whether gestational or lactational exposure is most relevant for (OH-)PBDE-induced developmental neurotoxicity in humans. The lower exposure during a sensitive (possibly prenatal) developmental phase may be more hazardous for the developing fetal brain than higher exposure during the next (possibly postnatal) developmental phase via for example, lactational transfer. Further research on neurodevelopment and cognitive and behavioral function, in particularly with respect to disruption by external stimuli, including xenobiotics, is therefore required.

Partitioning of PBDEs into the (fetal) brain is detected in wildlife ([@r7]; [@r40]; [@r80]) and toxicokinetics studies, often by using radiolabeled PBDEs ([@r84]; [@r93]; [@r106], [@r107]). In contrast, recent experimental and wildlife studies have shown that OH-PBDEs are usually not detectable in brain, although OH-PBDEs were detected in brain and cerebrospinal fluids of marine mammals ([@r40]; [@r80]; [@r134]). Nonetheless, it should be recognized that for some OH-PCBs, specific accumulation in brain tissue occurs, which has been suggested to be associated with binding to TTR ([@r76]; [@r82]). OH-PBDEs also strongly bind to TTR as well as to T~4~-binding globulin (TBG), which is the main transporter protein for thyroid hormones in humans across the blood--brain barrier ([@r73]). Because of the discrepancy between observations in wildlife and toxicokinetics studies with parent PBDEs, as well as the demonstrated accumulating properties of the structurally related (OH-)PCBs, the potential of OH-PBDEs to enter the brain requires further study.

For most classes of chemicals, risk assessment is based on exposure and hazard assessment of single compounds, with the exception of the toxic equivalency approach for dioxins and dioxin-like compounds ([@r116]). In reality, however, the human exposure pattern includes a plethora of chemicals, including environmental and dietary (OH-)PBDE exposure and those originating from systemic metabolic conversion. For the latter aspect, interindividual differences commonly occur ([@r53]). Because of the observed similarities in effects on neurobehavior and on acute *in vitro* effects related to neuronal signaling, there is a scientific rationale to use concentration addition as the default precautionary approach for risk assessment of mixtures of PBDEs, PCBs, and their metabolites. Because of the possible additivity of these environmental pollutants at levels below effective concentrations of the individual congeners and because of the higher sensitivity of the developing brain, mixture effects must be taken into account for human risk assessment for developmental neurotoxicity and investigated further.

Although the use of PBDEs has been greatly reduced in most countries because of voluntary and legislative measures, humans and wildlife will still be exposed to PBDEs and their metabolites for many years to come because of their environmental persistence and the fact that consumer products with these flame retardants are still present in many homes. This also underscores the necessity of implementing better hazard and risk assessment strategies for identifying human health risks of new chemicals, such as novel halogenated flame retardants. More knowledge on oxidative metabolism and the possible bioactivation of PBDEs, the sensitivity to neurotoxicity during specific processes of brain development, the concentrations of (OH-)PBDEs in the brain, and the interactions between different environmental contaminants during simultaneous exposure is currently required to further improve the assessment of neurotoxic risk of PBDEs, their metabolites, and related environmental contaminants.
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